ReviewBiosensors2023
Surface Plasmon Resonance (SPR) Sensor for Cancer Biomarker Detection.
Review in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Immunoinformatics-driven multi-epitope vaccine design as a promising strategy against multidrug-resistant pathogens: a comprehensive review.Folia microbiologica · 2026Review
- A π-Configuration Plasmonic Dual Surface Plasmon Resonance Fiber Optic Sensor for Multi-Analyte Detection.Sensors (Basel, Switzerland) · 2026Article
- Smart label-free SPR biosensing platform for hemoglobin and urine glucose detection via machine learning.Scientific reports · 2026Article
- Proof-of-concept study of clinical use of blood-based MAVS biosensor in predicting immunotherapy response in SCLC patients.Translational oncology · 2026Article
- Recent Progress in Nanophotonics for Green Energy, Medicine, Healthcare, and Optical Computing Applications.Materials (Basel, Switzerland) · 2026Review
- Identification of diagnostic and prognostic biomarkers in lung adenocarcinoma through integrated bioinformatics analysis and real time PCR validation.Scientific reports · 2026Article
- Enhanced Sensitivity in D-Shaped Optical Fiber SPR Sensor via Ag-α-FeMicromachines · 2026Article
- Sensitivity enhancement of surface plasmon resonance biosensors based on versatile nanostructures: principle, fabrication, and illustrative applications.Microsystems & nanoengineering · 2026Review
- Portable and label-free optical detection of sweat glucose using functionalized plasmonic nanopillar array.Microsystems & nanoengineering · 2026Article
- Design of Functionalized Photon Sieves for the Detection of Biomarkers in Running Fluids.Sensors (Basel, Switzerland) · 2026Article
- Integration of Nanotechnology with ctDNA: New Advances for Monitoring Neoadjuvant Chemotherapy.International journal of nanomedicine · 2026Review
- Lighting the Path to Precision Healthcare: Advances and Applications of Wearable Photonic Sensors.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Review
- Matrix Optical Biosensor for Determining YKL-40/CHI3L1-A Biomarker Potentially Associated with Alzheimer's Disease.Biosensors · 2025Article
- Rapid and Quantitative Detection of TNF-α in Human Tears Using a Portable Electrochemiluminescence-Based Device.Biosensors · 2025Article
- Lysozyme detection in body biofluids by dual-decorated graphene oxide-gold nanoparticles-based biomimetic plasmonic sensor.Mikrochimica acta · 2025Article
- Advances in Label-Free Detection of Non-Muscle Invasive Bladder Cancer: A Critical Review.Bioengineering (Basel, Switzerland) · 2025Review
- Graphene-Based Plasmonic Antenna for Advancing Nano-Scale Sensors.Nanomaterials (Basel, Switzerland) · 2025Review
- Development of an SPRi Immune Method for the Quantitative Detection of Osteopontin.Sensors (Basel, Switzerland) · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A biomarker is a physiological observable marker that acts as a stand-in and, in the best-case scenario, forecasts a clinically significant outcome. Diagnostic biomarkers are more convenient and cost-effective than directly measuring the ultimate clinical outcome. Cancer is among the most prominent global health problems and a major cause of morbidity and death globally. Therefore, cancer biomarker assays that are trustworthy, consistent, precise, and verified are desperately needed. Biomarker-based tumor detection holds a lot of promise for improving disease knowledge at the molecular scale and early detection and surveillance. In contrast to conventional approaches, surface plasmon resonance (SPR) allows for the quick and less invasive screening of a variety of circulating indicators, such as circulating tumor DNA (ctDNA), microRNA (miRNA), circulating tumor cells (CTCs), lipids, and proteins. With several advantages, the SPR technique is a particularly beneficial choice for the point-of-care identification of biomarkers. As a result, it enables the timely detection of tumor markers, which could be used to track cancer development and suppress the relapse of malignant tumors. This review emphasizes advancements in SPR biosensing technologies for cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.